Lexicon Pharmaceuticals, INC

Lexicon Pharmaceuticals announced its first quarter 2026 financial results, highlighting progress in its cardiometabolic pipeline, including updates on sotagliflozin and ZYNQUISTA, alongside a strengthened financial position.

Lexicon Pharmaceuticals has entered into a $100 million loan and security agreement with Hercules Capital, providing significant financial flexibility and capital to support its pipeline and upcoming milestones.

Lexicon Pharmaceuticals reported its fourth quarter and full-year 2025 financial results, highlighting significant pipeline progress and a strengthened financial position.

Lexicon Pharmaceuticals announced the pricing of a public offering and concurrent private placement, raising approximately $94.6 million to fund research and development.

Lexicon Pharmaceuticals initiated an underwritten public offering and a concurrent private placement to fund research and development, while also providing updates on its clinical pipeline and cash position.

Lexicon Pharmaceuticals, Inc. filed an 8-K to correct an inadvertent statement in a prospectus supplement regarding an audit of internal controls, related to its ongoing $75 million at-the-market stock offering.

Lexicon Pharmaceuticals reports a significant revenue increase driven by milestone payments, alongside a reduced net loss for the first quarter of 2026.

Lexicon Pharmaceuticals reported a significantly reduced net loss for Q3 2025, driven by a substantial licensing agreement with Novo Nordisk and aggressive cost-cutting measures.

Lexicon Pharmaceuticals reported a significantly reduced net loss for the six months ended June 30, 2025, driven by a substantial licensing agreement with Novo Nordisk and reduced operating expenses.

Lexicon Pharmaceuticals announces its Q1 2025 financial results, featuring a licensing agreement with Novo Nordisk for LX9851 and a prepayment of $45 million on its Oxford Term Loans.

Lexicon Pharmaceuticals reported its third quarter 2024 financial results, showing increased revenue from INPEFA sales and ongoing development of its drug pipeline.

Lexicon Pharmaceuticals saw a rise in product revenue driven by INPEFA sales, but also experienced increased operating expenses and net losses in the second quarter of 2024.

Lexicon Pharmaceuticals' 2025 annual report highlights significant pipeline advancements, including key licensing deals and a reduced net loss, despite ongoing regulatory challenges for ZYNQUISTA.

Lexicon Pharmaceuticals' 2024 10-K filing highlights ongoing drug development, commercialization efforts, and a strategic licensing agreement with Viatris.

Lexicon Pharmaceuticals' 2023 annual report details the commercial launch of INPEFA for heart failure, progress in sotagliflozin development for type 1 diabetes and hypertrophic cardiomyopathy, and advancement of LX9211 for neuropathic pain.

Judith L. Swain, a Director at Lexicon Pharmaceuticals, Inc., reported the acquisition of 89,312 shares of common stock on June 3, 2026, through the vesting of restricted stock units.

Lexicon Pharmaceuticals Director Diane E. Sullivan acquired 89,312 shares of common stock through the vesting of restricted stock units.

Lexicon Pharmaceuticals Director Christopher J. Sobecki acquired 89,312 shares of common stock through the vesting of restricted stock units.

Ivan Cheung, a Director at Lexicon Pharmaceuticals, reported the acquisition of 89,312 shares of common stock upon the vesting of restricted stock units.

Lexicon Pharmaceuticals Director Sam L. Barker acquired 89,312 shares of common stock through the vesting of restricted stock units.

Lexicon Pharmaceuticals Director Philippe Amouyal reported the acquisition of 89,312 shares of common stock.

Lexicon Pharmaceuticals, Inc. invites stockholders to its 2026 annual meeting to vote on director elections, an increase in authorized common stock, new equity incentive plans, executive compensation, and auditor ratification.

Lexicon Pharmaceuticals has filed a definitive proxy statement with the SEC, indicating upcoming shareholder actions.

Lexicon Pharmaceuticals is asking stockholders to approve a reverse stock split and amendments to its equity incentive plans at its upcoming annual meeting.

Lexicon Pharmaceuticals has filed a definitive proxy statement with the SEC, indicating upcoming shareholder actions.

Lexicon Pharmaceuticals is holding its annual stockholder meeting on May 10, 2024, to vote on key proposals including director elections, increasing authorized shares, executive compensation, and auditor ratification.

Major shareholders of Lexicon Pharmaceuticals have converted preferred stock into over 20 million common shares, bringing their collective ownership to 51.1%.

Lexicon Pharmaceuticals, Inc. announced a significant equity financing round, including a public offering and private placements, raising over $58 million from major shareholders and institutional investors.

FMR LLC and Abigail P. Johnson have disclosed a combined beneficial ownership of 10.5% of Lexicon Pharmaceuticals Inc.'s common stock, totaling 38,137,535 shares, as of June 30, 2025.

FMR LLC and its affiliates, along with Abigail P. Johnson, reported a continued beneficial ownership of 9.6% of Lexicon Pharmaceuticals Inc.'s common stock as of March 31, 2025.